RNA 표적 저분자 Drug Discovery 시장 : 시장 규모, 점유율, 동향 분석 보고서 - 적응증별, 최종 용도별, 지역별, 부문 예측, 부문 예측(2025-2030년)

RNA Targeting Small Molecule Drug Discovery Market Size, Share & Trends Analysis Report By Indication (Cancer, Infectious Diseases, Metabolic Diseases, Neurological Diseases), By End-use, By Region, And Segment Forecasts, 2025 - 2030

US $ 5,950 ￦ 8,176,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 9,550,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 12,299,000

Printable PDF & Excel (Enterprise License)

보고서 구매 기업 및 그 자회사, 관계사가 사용할 수 있는 라이선스이며, PDF 및 엑셀 텍스트 등의 복사 및 붙여넣기, 인쇄가 가능합니다.

한글목차

RNA 표적 저분자 Drug Discovery 시장의 성장 및 동향 :

Grand View Research, Inc.의 최신 보고서에 따르면 세계의 RNA 표적 저분자 Drug Discovery 시장 규모는 2025-2030년 21.9%의 연평균 복합 성장률(CAGR)을 기록할 전망이며, 2030년까지 54억 2,000만 달러에 이를 것으로 추정되고 있습니다.

RNA 표적 저분자 Drug Discovery 산업은 다양한 질병에 대한 표적화되고 효과적인 치료제를 개발할 수 있기 때문에 급성장을 계속하고 있습니다.

암, 유전성 질환, 바이러스 감염 등의 질병 유병률 증가가 RNA 표적 저분자 약물 수요를 부추기고 있습니다. RNA 표적 저분자 Drug Discovery 산업은 CRISPR-Cas9 및 RNA 간섭과 같은 최첨단 기술의 도입에 의해 극적으로 성장했습니다. 이러한 기술에 의해 질병의 발병에 관여하는 RNA 표적의 동정이 가능해져 RNA를 표적으로 하는 완전히 새로운 저분자 의약품이 만들어지고 있습니다.

향후 수년간, Drug Discovery를 위한 RNA 표적 저분자 시장은 제약회사나 바이오테크놀러지 기업에 의한 연구개발 활동에 대한 지출 증가에 견인되어, 대폭적인 확대가 예상됩니다. 혁신적인 RNA 표적 저분자를 창제하는 과정에는 시간과 비용이 들지만 집중적이고 효율적인 치료라는 잠재적 보상을 받을 수 있기 때문에 투자할 만합니다.

예를 들어, 2020년에 모데나가 버텍스 파머슈티칼스와 공동으로 실시한 낭포성 섬유증 치료용 RNA 표적 저분자 의약품의 개발은 이 분야에 대한 중요한 투자입니다. 모더나는 자사의 mRNA 기술 플랫폼을 사용해 신규 RNA 표적을 동정하고, 버텍스는 저분자 신약의 전문 지식을 응용해 표적에 대한 치료법을 개발합니다. 이 제휴는, 질환 치료에 혁명을 가져올 가능성을 내포한 RNA 표적 저분자 Drug Discovery에 대한 관심과 투자의 고조를 반영하고 있습니다.

RNA 표적 저분자 Drug Discovery 시장 보고서 하이라이트

• 적응증에서는 암이 예측 기간 중 22.3%로 가장 높은 CAGR을 나타냈습니다. 이 분야의 고성장은 암 유병률의 증가와 보다 효과적인 치료법의 긴급한 요구에 기인합니다.
• RNA 표적 저분자 Drug Discovery 업계에서는 제약 및 바이오 제약 기업이 최종 사용자 부문에서 우위를 차지하고 있어 2024년 시장 점유율은 59.4%였습니다. 이는 이 분야의 연구개발 활동에 대한 많은 투자와 신약을 시장에 투입하기 위한 전문 지식에 의한 것입니다.
• 북미는 2024년에 세계 시장의 60.7%라는 최대의 매출 점유율을 차지했지만, 이는 주요 시장 기업의 존재, 고도의 헬스케어 인프라, 연구개발 활동에 대한 투자 증가 등의 요인에 의한 것입니다. 이 지역은, 신치요법의 개발과 상업화를 지원하는 의료 제도가 확립되어 있어, 이것이 이 시장에서 우위성의 한 요인이 되고 있습니다.

목차

제1장 조사 방법 및 범위

제2장 주요 요약

제3장 RNA 표적 저분자 Drug Discovery 시장의 변수, 동향 및 범위

• 시장 계통 전망
• 시장 역학
  • 시장 성장 촉진요인 분석
  • 시장 성장 억제요인 분석
• 비즈니스 환경 분석
  • 업계 분석-Porter's Five Forces 분석
  • PESTLE 분석

제4장 RNA 표적 저분자 Drug Discovery 시장 : 적응증별 비즈니스 분석

• 적응증별 시장 점유율(2024년, 2030년)
• 적응증별 부문 대시보드
• 시장 규모, 예측 및 동향 분석 : 적응증별(2018-2030년)
• 암
• 감염증
• 대사성 질환
• 신경질환
• 기타

제5장 RNA 표적 저분자 Drug Discovery 시장 : 최종 용도별 비즈니스 분석

• 최종 용도별 시장 점유율(2024년, 2030년)
• 최종 용도별 부문 대시보드
• 시장 규모, 예측 및 동향 분석 : 최종 용도별(2018-2030년)
• 제약회사 및 바이오의약품회사
• 학술연구기관
• 기타

제6장 RNA 표적 저분자 Drug Discovery 시장 : 지역별 추정 및 동향 분석

• 지역별 시장 점유율 분석(2024년, 2030년)
• 지역별 시장 대시보드
• 시장 규모, 예측 및 동향 분석(2018-2030년)
• 북미
  • 국가별(2018-2030년)
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 국가별(2018-2030년)
  • 영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 노르웨이
  • 덴마크
  • 스웨덴
• 아시아태평양
  • 국가별(2018-2030년)
  • 일본
  • 중국
  • 인도
  • 한국
  • 호주
  • 태국
• 라틴아메리카
  • 국가별(2018-2030년)
  • 브라질
  • 아르헨티나
• 중동 및 아프리카
  • 국가별(2018-2030년)
  • 남아프리카
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 쿠웨이트

제7장 경쟁 구도

• 참가자 개요
• 기업의 시장 포지셔닝 분석
• 기업 분류
• 전략 매핑
• 기업 프로파일 및 목록
  • ACCENT THERAPEUTICS
  • Anima Biotech Inc.
  • Arrakis Therapeutics
  • AstraZeneca
  • Epics Therapeutics
  • Expansion Therapeutics
  • F. Hoffmann-La Roche Ltd
  • PTC Therapeutics, Inc.
  • Ribometrix
  • LES LABORATOIRES SERVIER
  • Skyhawk Therapeutics

AJY

영문 목차

영문목차

RNA Targeting Small Molecule Drug Discovery Market Growth & Trends:

The global RNA targeting small molecule drug discovery market size is estimated to reach USD 5.42 billion by 2030, registering a CAGR of 21.9% from 2025 to 2030, according to a new report by Grand View Research, Inc. RNA-targeting small molecule drug discovery industry continues to undergo rapid growth due to its potential to develop targeted and effective therapeutics for various diseases.

The increasing prevalence of diseases such as cancer, genetic disorders, and viral infections has fueled the demand for RNA-targeting small-molecule drugs. The RNA-targeting small molecule drug discovery industry has grown dramatically as a result of the introduction of cutting-edge technologies like CRISPR-Cas9 and RNA interference. These technologies have made it possible to identify RNA targets that are implicated in the pathogenesis of diseases, which has resulted in the creation of brand-new small-molecule medications that target RNA.

In the upcoming years, the market for RNA targeting small molecules for drug discovery is anticipated to experience significant expansion, driven by the rising expenditure in R&D activities by pharmaceutical and biotechnology businesses. The process of creating innovative, RNA-targeting small molecules is time-consuming and costly, but the potential rewards of focused, efficient treatments make it a worthy investment.

For instance, in 2020 Moderna's recent collaboration with Vertex Pharmaceuticals to develop RNA-targeted small molecule drugs for the treatment of cystic fibrosis is a significant investment in this field. Moderna will use its mRNA technology platform to identify novel RNA targets, while Vertex will apply its expertise in small molecule drug discovery to develop therapies for the targets. This collaboration reflects the growing interest and investment in RNA-targeting small molecule drug discovery, which has the potential to revolutionize disease treatment.

RNA Targeting Small Molecule Drug Discovery Market Report Highlights:

• Cancer in the indication segment witnessed the highest CAGR of 22.3% ovre the forecast period. The high growth of the segment is majorly due to the increasing prevalence of cancer and the urgent need for more effective treatments.
• Pharmaceutical and biopharmaceutical companies dominated the RNA-targeting small molecule drug discovery industry in the end-user segment, with a market share of 59.4% in 2024. This is due to their significant investment in research and development activities in this field, as well as their expertise in bringing new drugs to market.
• North America held the maximum revenue share of 60.7% of the global market in 2024, due to factors such as the presence of key market players, advanced healthcare infrastructure, and increasing investment in research and development activities. This region has a well-established healthcare system that supports the development and commercialization of new therapies, which contributes to its dominance in the market.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Indication
  • 1.2.2. End Use
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
• 1.6. Information Analysis
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Data Visualization
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
• 1.9. List of Secondary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. RNA Targeting Small Molecule Drug Discovery Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Business Environment Analysis
  • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
    • 3.3.1.1. Supplier Power
    • 3.3.1.2. Buyer Power
    • 3.3.1.3. Substitution Threat
    • 3.3.1.4. Threat of New Entrants
    • 3.3.1.5. Competitive Rivalry
  • 3.3.2. PESTLE Analysis

Chapter 4. RNA Targeting Small Molecule Drug Discovery Market: Indication Business Analysis

• 4.1. Indication Market Share, 2024 & 2030
• 4.2. Indication Segment Dashboard
• 4.3. Market Size & Forecasts and Trend Analysis, by Indication, 2018 to 2030 (USD Million)
• 4.4. Cancer
  • 4.4.1. Cancer Market, 2018 - 2030 (USD Million)
• 4.5. Infectious Diseases
  • 4.5.1. Infectious Diseases Market, 2018 - 2030 (USD Million)
• 4.6. Metabolic Diseases
  • 4.6.1. Metabolic Diseases Market, 2018 - 2030 (USD Million)
• 4.7. Neurological Diseases
  • 4.7.1. Neurological Diseases Market, 2018 - 2030 (USD Million)
• 4.8. Others
  • 4.8.1. Others Market, 2018 - 2030 (USD Million)

Chapter 5. RNA Targeting Small Molecule Drug Discovery Market: End Use Business Analysis

• 5.1. End Use Market Share, 2024 & 2030
• 5.2. End Use Segment Dashboard
• 5.3. Market Size & Forecasts and Trend Analysis, by End Use, 2018 to 2030 (USD Million)
• 5.4. Pharmaceutical and Biopharmaceutical Companies
  • 5.4.1. Pharmaceutical and Biopharmaceutical Companies Market, 2018 - 2030 (USD Million)
• 5.5. Academic and Research Institutes
  • 5.5.1. Academic and Research Institutes Market, 2018 - 2030 (USD Million)
• 5.6. Others
  • 5.6.1. Others Market, 2018 - 2030 (USD Million)

Chapter 6. RNA Targeting Small Molecule Drug Discovery Market: Regional Estimates & Trend Analysis

• 6.1. Regional Market Share Analysis, 2024 & 2030
• 6.2. Regional Market Dashboard
• 6.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 6.4. North America
  • 6.4.1. North America RNA Targeting Small Molecule Drug Discovery Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
  • 6.4.2. U.S.
    • 6.4.2.1. Key Country Dynamics
    • 6.4.2.2. Regulatory Framework
    • 6.4.2.3. Competitive Insights
    • 6.4.2.4. U.S. RNA Targeting Small Molecule Drug Discovery Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.4.3. Canada
    • 6.4.3.1. Key Country Dynamics
    • 6.4.3.2. Regulatory Framework
    • 6.4.3.3. Competitive Insights
    • 6.4.3.4. Canada RNA Targeting Small Molecule Drug Discovery Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.4.4. Mexico
    • 6.4.4.1. Key Country Dynamics
    • 6.4.4.2. Regulatory Framework
    • 6.4.4.3. Competitive Insights
    • 6.4.4.4. Mexico RNA Targeting Small Molecule Drug Discovery Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 6.5. Europe
  • 6.5.1. Europe RNA Targeting Small Molecule Drug Discovery Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
  • 6.5.2. UK
    • 6.5.2.1. Key Country Dynamics
    • 6.5.2.2. Regulatory Framework
    • 6.5.2.3. Competitive Insights
    • 6.5.2.4. UK RNA Targeting Small Molecule Drug Discovery Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.5.3. Germany
    • 6.5.3.1. Key Country Dynamics
    • 6.5.3.2. Regulatory Framework
    • 6.5.3.3. Competitive Insights
    • 6.5.3.4. Germany RNA Targeting Small Molecule Drug Discovery Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.5.4. France
    • 6.5.4.1. Key Country Dynamics
    • 6.5.4.2. Regulatory Framework
    • 6.5.4.3. Competitive Insights
    • 6.5.4.4. France RNA Targeting Small Molecule Drug Discovery Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.5.5. Italy
    • 6.5.5.1. Key Country Dynamics
    • 6.5.5.2. Regulatory Framework
    • 6.5.5.3. Competitive Insights
    • 6.5.5.4. Italy RNA Targeting Small Molecule Drug Discovery Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.5.6. Spain
    • 6.5.6.1. Key Country Dynamics
    • 6.5.6.2. Regulatory Framework
    • 6.5.6.3. Competitive Insights
    • 6.5.6.4. Spain RNA Targeting Small Molecule Drug Discovery Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.5.7. Norway
    • 6.5.7.1. Key Country Dynamics
    • 6.5.7.2. Regulatory Framework
    • 6.5.7.3. Competitive Insights
    • 6.5.7.4. Norway RNA Targeting Small Molecule Drug Discovery Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.5.8. Denmark
    • 6.5.8.1. Key Country Dynamics
    • 6.5.8.2. Regulatory Framework
    • 6.5.8.3. Competitive Insights
    • 6.5.8.4. Denmark RNA Targeting Small Molecule Drug Discovery Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.5.9. Sweden
    • 6.5.9.1. Key Country Dynamics
    • 6.5.9.2. Regulatory Framework
    • 6.5.9.3. Competitive Insights
    • 6.5.9.4. Sweden RNA Targeting Small Molecule Drug Discovery Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 6.6. Asia Pacific
  • 6.6.1. Asia Pacific RNA Targeting Small Molecule Drug Discovery Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
  • 6.6.2. Japan
    • 6.6.2.1. Key Country Dynamics
    • 6.6.2.2. Regulatory Framework
    • 6.6.2.3. Competitive Insights
    • 6.6.2.4. Japan RNA Targeting Small Molecule Drug Discovery Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.6.3. China
    • 6.6.3.1. Key Country Dynamics
    • 6.6.3.2. Regulatory Framework
    • 6.6.3.3. Competitive Insights
    • 6.6.3.4. China RNA Targeting Small Molecule Drug Discovery Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.6.4. India
    • 6.6.4.1. Key Country Dynamics
    • 6.6.4.2. Regulatory Framework
    • 6.6.4.3. Competitive Insights
    • 6.6.4.4. India RNA Targeting Small Molecule Drug Discovery Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.6.5. South Korea
    • 6.6.5.1. Key Country Dynamics
    • 6.6.5.2. Regulatory Framework
    • 6.6.5.3. Competitive Insights
    • 6.6.5.4. South Korea RNA Targeting Small Molecule Drug Discovery Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.6.6. Australia
    • 6.6.6.1. Key Country Dynamics
    • 6.6.6.2. Regulatory Framework
    • 6.6.6.3. Competitive Insights
    • 6.6.6.4. Australia RNA Targeting Small Molecule Drug Discovery Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.6.7. Thailand
    • 6.6.7.1. Key Country Dynamics
    • 6.6.7.2. Regulatory Framework
    • 6.6.7.3. Competitive Insights
    • 6.6.7.4. Thailand RNA Targeting Small Molecule Drug Discovery Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 6.7. Latin America
  • 6.7.1. Latin America RNA Targeting Small Molecule Drug Discovery Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
  • 6.7.2. Brazil
    • 6.7.2.1. Key Country Dynamics
    • 6.7.2.2. Regulatory Framework
    • 6.7.2.3. Competitive Insights
    • 6.7.2.4. Brazil RNA Targeting Small Molecule Drug Discovery Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.7.3. Argentina
    • 6.7.3.1. Key Country Dynamics
    • 6.7.3.2. Regulatory Framework
    • 6.7.3.3. Competitive Insights
    • 6.7.3.4. Argentina RNA Targeting Small Molecule Drug Discovery Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 6.8. MEA
  • 6.8.1. MEA RNA Targeting Small Molecule Drug Discovery Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
  • 6.8.2. South Africa
    • 6.8.2.1. Key Country Dynamics
    • 6.8.2.2. Regulatory Framework
    • 6.8.2.3. Competitive Insights
    • 6.8.2.4. South Africa RNA Targeting Small Molecule Drug Discovery Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.8.3. Saudi Arabia
    • 6.8.3.1. Key Country Dynamics
    • 6.8.3.2. Regulatory Framework
    • 6.8.3.3. Competitive Insights
    • 6.8.3.4. Saudi Arabia RNA Targeting Small Molecule Drug Discovery Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.8.4. UAE
    • 6.8.4.1. Key Country Dynamics
    • 6.8.4.2. Regulatory Framework
    • 6.8.4.3. Competitive Insights
    • 6.8.4.4. UAE RNA Targeting Small Molecule Drug Discovery Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.8.5. Kuwait
    • 6.8.5.1. Key Country Dynamics
    • 6.8.5.2. Regulatory Framework
    • 6.8.5.3. Competitive Insights
    • 6.8.5.4. Kuwait RNA Targeting Small Molecule Drug Discovery Market Estimates And Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Participant Overview
• 7.2. Company Market Position Analysis
• 7.3. Company Categorization
• 7.4. Strategy Mapping
• 7.5. Company Profiles/Listing
  • 7.5.1. ACCENT THERAPEUTICS
    • 7.5.1.1. Overview
    • 7.5.1.2. Financial Performance
    • 7.5.1.3. Product Benchmarking
    • 7.5.1.4. Strategic Initiatives
  • 7.5.2. Anima Biotech Inc.
    • 7.5.2.1. Overview
    • 7.5.2.2. Financial Performance
    • 7.5.2.3. Product Benchmarking
    • 7.5.2.4. Strategic Initiatives
  • 7.5.3. Arrakis Therapeutics
    • 7.5.3.1. Overview
    • 7.5.3.2. Financial Performance
    • 7.5.3.3. Product Benchmarking
    • 7.5.3.4. Strategic Initiatives
  • 7.5.4. AstraZeneca
    • 7.5.4.1. Overview
    • 7.5.4.2. Financial Performance
    • 7.5.4.3. Product Benchmarking
    • 7.5.4.4. Strategic Initiatives
  • 7.5.5. Epics Therapeutics
    • 7.5.5.1. Overview
    • 7.5.5.2. Financial Performance
    • 7.5.5.3. Product Benchmarking
    • 7.5.5.4. Strategic Initiatives
  • 7.5.6. Expansion Therapeutics
    • 7.5.6.1. Overview
    • 7.5.6.2. Financial Performance
    • 7.5.6.3. Product Benchmarking
    • 7.5.6.4. Strategic Initiatives
  • 7.5.7. F. Hoffmann-La Roche Ltd
    • 7.5.7.1. Overview
    • 7.5.7.2. Financial Performance
    • 7.5.7.3. Product Benchmarking
    • 7.5.7.4. Strategic Initiatives
  • 7.5.8. PTC Therapeutics, Inc.
    • 7.5.8.1. Overview
    • 7.5.8.2. Financial Performance
    • 7.5.8.3. Product Benchmarking
    • 7.5.8.4. Strategic Initiatives
  • 7.5.9. Ribometrix
    • 7.5.9.1. Overview
    • 7.5.9.2. Financial Performance
    • 7.5.9.3. Product Benchmarking
    • 7.5.9.4. Strategic Initiatives
  • 7.5.10. LES LABORATOIRES SERVIER
    • 7.5.10.1. Overview
    • 7.5.10.2. Financial Performance
    • 7.5.10.3. Product Benchmarking
    • 7.5.10.4. Strategic Initiatives
  • 7.5.11. Skyhawk Therapeutics
    • 7.5.11.1. Overview
    • 7.5.11.2. Financial Performance
    • 7.5.11.3. Product Benchmarking
    • 7.5.11.4. Strategic Initiatives

관련자료